Chimerix's CMX001 meets CMV endpoint

Chimerix Inc. (Durham, N.C.) said twice-weekly 100 mg CMX001 met the primary endpoint in a Phase II trial (Study 201) to treat and prevent cytomegalovirus (CMV) infection in hematopoietic stem cell tr...